YRNA expression in prostate cancer patients: diagnostic and prognostic implications

World Journal of Urology
Yuri TolkachJörg Ellinger

Abstract

To study the expression of YRNAs (Ro-associated Y), a novel class of non-coding RNAs, in prostate cancer (PCA) patients. The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival PCA (prostate adenocarcinoma, n = 56), normal (n = 36) and benign prostatic hyperplasia (BPH; n = 28) tissues using quantitative real-time PCR. Associations with clinicopathological parameters and prognostic role for biochemical recurrence-free survival were analysed. All YRNAs were significantly downregulated in PCA tissue compared to normal tissue (all YRNAs) and to BPH tissue (RNY4 and RNY5; RNY1 and RNY3 as trend). Among tumor ISUP grade groups, the most prominent differences in the expression were evident between groups 1 and 2 (RNY1, RNY3 und RNY4; all p < 0.05). Discrimination ability for normal/BPH tissue versus tumor tissue in ROC analysis (area under curve) was ranging from 0.658 (RNY1) to 0.739 (RNY4). Higher RNY5 expression was associated with poor prognosis (biochemical recurrence-free survival). The expression of YRNAs is altered in PCA and associated with poor prognosis (RNY5). Possible diagnostic role of YRNAs in prostate cancer should be investigated in further studies.

References

Dec 14, 1993·Biochimica Et Biophysica Acta·G J PruijnW J van Venrooij
Sep 1, 2006·Molecular and Cellular Biology·Christo P ChristovTorsten Krude
Feb 20, 2008·British Journal of Cancer·C P ChristovT Krude
Jul 3, 2009·Genes & Development·Jeremy E WiluszDavid L Spector
Jul 14, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Imke SandersJörg Ellinger
Dec 18, 2012·Histopathology·Lars EgevadPhilippe Camparo
Feb 5, 2013·Cancer Letters·Elena S Martens-UzunovaGuido Jenster
Feb 27, 2015·Expert Review of Molecular Diagnostics·Jörg EllingerDimo Dietrich
Jun 10, 2015·Oncotarget·Berta Victoria MartinezMichal M Masternak
Sep 24, 2015·RNA·Sudipto K ChakraborttyThomas R Gingeras
Jul 3, 2016·European Urology·Sebastien AntoniFreddie Bray
Jan 6, 2017·Cell Death & Disease·Zoheir HizirEmanuela Repetto
Mar 18, 2017·Scientific Reports·Ashish YeriKendall Van Keuren-Jensen
Apr 27, 2017·Oncotarget·Daniela VanacoreGaetano Facchini
Jul 13, 2017·The New England Journal of Medicine·Timothy J WiltMichael K Brawer
Jul 30, 2017·European Urology Focus·Malin NientiedtJörg Ellinger
Nov 12, 2017·BMC Cancer·Yuri TolkachJörg Ellinger

❮ Previous
Next ❯

Citations

Oct 4, 2019·Current Pharmaceutical Biotechnology·Lifang HaoZhongcheng Liu
Aug 14, 2020·International Journal of Molecular Sciences·Kacper GuglasKatarzyna Lamperska
Sep 23, 2020·International Journal of Molecular Sciences·Melinda SzilágyiBálint Nagy
Jul 3, 2020·Genes & Development·Meghdad Yeganeh, Nouria Hernandez
Sep 10, 2020·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Tomasz KolendaKatarzyna Lamperska
Feb 21, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Wujun ChenDongming Xing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.